Major Depressive Disorder (MDD) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Major depressive disorder (MDD), also known as Depression, is a severe medical condition that disrupts various aspects of a person’s life, including mood, behavior, thought processes, and physical well-being. While sadness and grief are normal responses to life’s challenges, depression represents a more intense and prolonged state of emotional distress. There are also other related conditions, such as bipolar disorder (manic-depressive illness) and dysthymia. Bipolar disorder is characterized by alternating episodes of depression and mania. During manic episodes, individuals may experience extreme and inappropriate “high” emotions that can lead to risky and destructive behaviors. Dysthymia, on the other hand, exhibits symptoms similar to those of major depressive disorder but typically persists over a longer duration. The decline in hippocampal function is believed to play a role in depression by inhibiting the hypothalamic-pituitary-adrenal (HPA) axis, potentially contributing to the hypercortisolemia observed in depressed individuals. Furthermore, individuals with depression often exhibit elevated levels of pro-inflammatory markers such as C-reactive protein (CRP), interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α).
· According to research, the prevalence of major depressive disorder (MDD) differs significantly across geographies, including the US (7.1%, 16.2 M) and Japan (4.7%, 5.0 M). In the US, MDD sufferers were more likely to be women than non-sufferers and were significantly younger (ps<0.05).
Thelansis’s “Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder (MDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Major Depressive Disorder (MDD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Major Depressive Disorder (MDD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Major Depressive Disorder (MDD), Major Depressive Disorder (MDD) market outlook, Major Depressive Disorder (MDD) competitive landscape, Major Depressive Disorder (MDD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
